Cases No Longer Accepted for Invokana Heart Problems

Invokana (canagliflozin) is a new generation diabetes drug introduced in March 2013. However, as a growing number of individuals have switched to the new medication, the drug makers have been required to add a number of new warnings about the risk of serious side effects linked to Invokana, including diabetic ketoacidosis, foot and leg amputations,and kidney problems.

In addition to claims for individuals who experienced these injuries, the lawyers at Saiontz & Kirk, P.A. previously evaluated the potential for Invokana heart attack lawsuits. However, new cases are no longer being reviewed. This page is maintained for informational purposes only.

RELATED CASES: Potential Invokana lawsuits are still being evaluated for individuals who have experienced amputation problems following use of this similar diabetes drug.

Invokana Heart Side Effects

Invokana works in a unique way, impacting normal kidney functions to allow more sugar to pass from the body through urine. It is part of a new class of medications, known as sodium-glucose-cotransporter-2 (SGLT2) inhibitors. Other members of this class include Invokamet, Farxiga, Xigdue XR, Jardiance and Glyxambi.

Only two years after Invokana was introduced, the FDA first warned about serious health risks associated with the medication, issuing a drug safety communication about the link between Invokana and diabetic ketoacidosis in May 2015.

Diabetic ketoacidosis is a serious medical condition that often results in the need for hospitalization and could lead to death. While it is usually rare among patients with type 2 diabetes, which Invokana is designed to treat, a number of FDA adverse event reports have been received involving users of Invokana diagnosed with ketoacidosis.

On December 4, 2015, the agency indicated that new ketoacidosis warnings were being required for the entire class of diabetes drugs, advising patients to stop using the drug immediately and seek medical assistance if they began experiencing signs of ketoacidosis.

Ketoacidosis may also increase the risk of an Invokana myocardial infarction, more commonly known as a heart attack. In fact, some experts say that ketoacidosis affects the heart in such a way that it can be confused for a heart attack, referred to as a pseudo-infarction.

Symptoms of a potential Invokana heart attack may include:

  • Shortness of Breath
  • Pain in the chest, jaw, left arm or upper abdomen
  • Anxiety
  • Abnormal Heartbeat
  • Dizziness
  • Fatigue
  • Clammy Skin or Cold Sweats

The FDA has urged individuals to seek immediate medical attention if they experience symptoms of ketoacidosis on Invokana, including:

  • Breathing Difficulty or Respiratory Problems
  • Nausea, Vomiting or Abdominal Pain
  • Confusion, Fatigue or Sleepiness

Invokana Heart Injury Lawyers

If more detailed warnings and information had been provided about the potential Invokana cardiac risks, many users may have avoided a heart attack or other serious injury by choosing to use a different diabetes treatment or more carefully monitoring their health.

The attorneys at Saiontz & Kirk, P.A. previously reviewed whether financial compensation may be available due to the drug makers’ failure to warn about the link between Invokana and heart attacks. While it appears that the manufacturer placed their desire for profits before consumer safety by aggressively marketing the drug without adequately researching the side effects or warning about the heart risks, new cases are no longer being accepted by your law firm.